UPDATE: Stifel Nicolaus Terminates Coverage on Omthera Pharmaceuticals Following Acquisition by AstraZeneca

In a report published Tuesday, Stifel Nicolaus analyst Joel Sendek terminated coverage on

. In the report, Stifel Nicolaus noted, “We are discontinuing our coverage of Omthera Pharmaceuticals following its acquisition by AstraZeneca on July 18th. Our last rating on the stock was Hold.” Omthera Pharmaceuticals closed on Monday at $13.30.